107 related articles for article (PubMed ID: 14583460)
1. Critical elements of the immunoglobulin heavy chain gene enhancers for deregulated expression of bcl-2.
Heckman CA; Cao T; Somsouk L; Duan H; Mehew JW; Zhang CY; Boxer LM
Cancer Res; 2003 Oct; 63(20):6666-73. PubMed ID: 14583460
[TBL] [Abstract][Full Text] [Related]
2. The immunoglobulin heavy-chain gene 3' enhancers deregulate bcl-2 promoter usage in t(14;18) lymphoma cells.
Duan H; Heckman CA; Boxer LM
Oncogene; 2007 Apr; 26(18):2635-41. PubMed ID: 17043638
[TBL] [Abstract][Full Text] [Related]
3. NF-kappaB activates Bcl-2 expression in t(14;18) lymphoma cells.
Heckman CA; Mehew JW; Boxer LM
Oncogene; 2002 May; 21(24):3898-908. PubMed ID: 12032828
[TBL] [Abstract][Full Text] [Related]
4. Regulation of Bcl-2 expression by C/EBP in t(14;18) lymphoma cells.
Heckman CA; Wheeler MA; Boxer LM
Oncogene; 2003 Sep; 22(39):7891-9. PubMed ID: 12970736
[TBL] [Abstract][Full Text] [Related]
5. A bcl-2/IgH antisense transcript deregulates bcl-2 gene expression in human follicular lymphoma t(14;18) cell lines.
Capaccioli S; Quattrone A; Schiavone N; Calastretti A; Copreni E; Bevilacqua A; Canti G; Gong L; Morelli S; Nicolin A
Oncogene; 1996 Jul; 13(1):105-15. PubMed ID: 8700536
[TBL] [Abstract][Full Text] [Related]
6. Oct transcription factors mediate t(14;18) lymphoma cell survival by directly regulating bcl-2 expression.
Heckman CA; Duan H; Garcia PB; Boxer LM
Oncogene; 2006 Feb; 25(6):888-98. PubMed ID: 16186795
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanisms of transcriptional control of bcl-2 and c-myc in follicular and transformed lymphoma.
Arcinas M; Heckman CA; Mehew JW; Boxer LM
Cancer Res; 2001 Jul; 61(13):5202-6. PubMed ID: 11431360
[TBL] [Abstract][Full Text] [Related]
8. FAS death domain deletions and cellular FADD-like interleukin 1beta converting enzyme inhibitory protein (long) overexpression: alternative mechanisms for deregulating the extrinsic apoptotic pathway in diffuse large B-cell lymphoma subtypes.
Takahashi H; Feuerhake F; Kutok JL; Monti S; Dal Cin P; Neuberg D; Aster JC; Shipp MA
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3265-71. PubMed ID: 16740746
[TBL] [Abstract][Full Text] [Related]
9. NF-kappa B activity is required for the deregulation of c-myc expression by the immunoglobulin heavy chain enhancer.
Kanda K; Hu HM; Zhang L; Grandchamps J; Boxer LM
J Biol Chem; 2000 Oct; 275(41):32338-46. PubMed ID: 10931834
[TBL] [Abstract][Full Text] [Related]
10. The role of immunoglobulin kappa elements in c-myc activation.
Hörtnagel K; Mautner J; Strobl LJ; Wolf DA; Christoph B; Geltinger C; Polack A
Oncogene; 1995 Apr; 10(7):1393-401. PubMed ID: 7731690
[TBL] [Abstract][Full Text] [Related]
11. Deregulation of the proto-oncogene c-myc through t(8;22) translocation in Burkitt's lymphoma.
Gerbitz A; Mautner J; Geltinger C; Hörtnagel K; Christoph B; Asenbauer H; Klobeck G; Polack A; Bornkamm GW
Oncogene; 1999 Mar; 18(9):1745-53. PubMed ID: 10208435
[TBL] [Abstract][Full Text] [Related]
12. Activation of the c-myc p1 promoter in Burkitt's lymphoma by the hs3 immunoglobulin heavy-chain gene enhancer.
Hu HM; Kanda K; Zhang L; Boxer LM
Leukemia; 2007 Apr; 21(4):747-53. PubMed ID: 17287852
[TBL] [Abstract][Full Text] [Related]
13. Alternative translocation breakpoint cluster region 5' to BCL-6 in B-cell non-Hodgkin's lymphoma.
Butler MP; Iida S; Capello D; Rossi D; Rao PH; Nallasivam P; Louie DC; Chaganti S; Au T; Gascoyne RD; Gaidano G; Chaganti RS; Dalla-Favera R
Cancer Res; 2002 Jul; 62(14):4089-94. PubMed ID: 12124346
[TBL] [Abstract][Full Text] [Related]
14. Variable IgH chain enhancer activity in Burkitt's lymphomas suggests an additional, direct mechanism of c-myc deregulation.
Jain VK; Judde JG; Max EE; Magrath IT
J Immunol; 1993 Jun; 150(12):5418-28. PubMed ID: 8515068
[TBL] [Abstract][Full Text] [Related]
15. High levels of BACH2 associated with lower levels of BCL2 transcript abundance in t(14;18)(q21;q34) translocation positive non-Hodgkin's lymphoma.
Green M; Gandhi MK; Camilleri E; Marlton P; Lea R; Griffiths L
Leuk Res; 2009 May; 33(5):731-4. PubMed ID: 18929412
[TBL] [Abstract][Full Text] [Related]
16. PU.1 protein expression has a positive linear association with protein expression of germinal centre B cell genes including BCL-6, CD10, CD20 and CD22: identification of PU.1 putative binding sites in the BCL-6 promotor.
Torlakovic E; Malecka A; Myklebust JH; Tierens A; Aasheim HC; Nesland JM; Smeland E; Kvaløy S; Delabie J
J Pathol; 2005 Jul; 206(3):312-9. PubMed ID: 15892171
[TBL] [Abstract][Full Text] [Related]
17. Endothelin-1 induces glut1 transcription through enhanced interaction between Sp1 and NF-kappaB transcription factors.
Kao YS; Fong JC
Cell Signal; 2008 Apr; 20(4):771-8. PubMed ID: 18249093
[TBL] [Abstract][Full Text] [Related]
18. Dyad symmetry within the mouse 3' IgH regulatory region includes two virtually identical enhancers (C alpha3'E and hs3).
Saleque S; Singh M; Little RD; Giannini SL; Michaelson JS; Birshtein BK
J Immunol; 1997 May; 158(10):4780-7. PubMed ID: 9144492
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the human intestinal CD98 promoter and its regulation by interferon-gamma.
Yan Y; Dalmasso G; Sitaraman S; Merlin D
Am J Physiol Gastrointest Liver Physiol; 2007 Feb; 292(2):G535-45. PubMed ID: 17023546
[TBL] [Abstract][Full Text] [Related]
20. A placenta-specific enhancer of the human syncytin gene.
Cheng YH; Handwerger S
Biol Reprod; 2005 Sep; 73(3):500-9. PubMed ID: 15888734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
